# In This Issue of JAMA

August 15, 2017 Volume 318, Number 7 Pages 585-676

#### Research

# Approval of High-Risk Medical Device Supplements

619

The US Food and Drug Administration (FDA) requires manufacturers of high-risk medical devices to show that modifications to the devices are safe and effective. In a descriptive study of 83 clinical studies supporting the approval of 78 applications to the FDA for changes in the design, performance, or intended uses of a high-risk medical device, Zheng and colleagues found that less than half of the studies were randomized, blinded, or controlled, and most primary outcomes were based on surrogate end points that may not be valid predictors of clinical events. In an Editorial on this and another article in this issue, Califf suggests that substantial progress in balancing safety with access to effective therapies will result from major changes to the system of drug and device approval.

Editorial 614 Related Article 626

Author Audio Interview jama.com CME jamanetwork.com/learning

# Quality of Evidence for Drugs Granted Accelerated Approval

Under its accelerated approval provision, the FDA may consider studies with surrogate measures of clinical outcomes in the approval of drugs for serious or life-threatening conditions, but after approval sponsors must conduct confirmatory trials with clinical end points such as overall survival. In a study of 22 drugs granted accelerated approval, Naci and colleagues found that many confirmatory trials had not been completed or had failed to show clinical benefit, and all but one of the primary end points of 18 completed confirmatory studies were surrogate measures.

Editorial 614 Related Article 619

■ Author Audio Interview jama.com CME jamanetwork.com/learning

# An Intensive Lifestyle Intervention for Glycemic Control

63/

Patients with type 2 diabetes mellitus can achieve glycemic control with pharmacological therapy, weight reduction, and modifications to diet and physical activity. In this preliminary randomized clinical trial of 98 adults with non-insulin-dependent type 2 diabetes, Johansen and colleagues found that participants who received a diet and exercise intervention plus standard care had a greater mean reduction in hemoglobin  $A_{ic}$  level than participants who received standard care alone. Further research is needed to assess the clinical benefits of the intervention.

#### Humanities

Poetry and Medicine 671 A Song of Hope

JAMA Revisited

672 Politics and the Medical Profession

#### **O**pinion

#### **V**iewpoi

605 Consideration of Dental, Vision, and Hearing Services to Be Covered Under Medicare

A Willink, C Schoen, and K Davis

607 Diagnostic Stewardship— Leveraging the Laboratory to Improve Antimicrobial Use DJ Morgan, P Malani, and DJ Diekema

609 Value-Based Pricing and State Reform of Prescription Drug Costs 11 Hwang, AS Kesselheim, and A Sarpatwan

#### A Piece of My Mind

611 Climate Change: What Would Lincoln Do?

WG Kaelin Jr

612 Trials and Tribulations
JL Brown

#### Editorial

614 Balancing the Need for Access With the Imperative for Empirical Evidence of Benefit and Risk RM Califf

617 Shared Decision Making and Improving Health-Care: The Answer Is Not In VM Monton, M Kunneman, and JP Brito

### LETTERS

#### Research Letter

662 Public Response to a Proposed Field Trial of Genetically Engineered Mosquitoes in the United States CS Bloss and Coauthors

### Comment & Response

664 Prenatal Antidepressant Use and Autism Spectrum Disorder

665 Maternal Antidepressant Use and Pregnancy Outcomes

667 Alveolar Recruitment Strategies After Cardiac Surgery

669 Correction

Editor in Chief Howard Bauchner, MD 134 YEARS OF CONTINUOUS PUBLICATION


# In This Issue of JAMA

August 15, 2017 Volume 318, Number 7 Pages 585-676

#### Clinical Review & Education

# **Celiac Disease and Nonceliac Gluten Sensitivity**

647



Celiac disease is a chronic, small intestinal immune-mediated enteropathy initiated by exposure to dietary gluten in genetically predisposed individuals. Leonard and colleagues review the clinical management of celiac disease and nonceliac gluten sensitivity.

■ CME jamanetwork.com/learning

# **Engaging Patients in Decisions for Screening or Treatment**

657

Patient decision aids are printed booklets, videos, or web-based tools to facilitate discussions about the benefits and harms of interventions for specific health conditions. In this JAMA Clinical Evidence Synopsis of 105 trials, Stacey and colleagues conclude that patient decision aids can help patients understand their options, assess risks, and make decisions consistent with their values. In an Editorial, Montori and colleagues discuss the limitations of available research and suggest that important questions about the effectiveness of patient decision aids have not been adequately addressed.

Editorial 617

# From The Medical Letter: Bezlotoxumab for C difficile Infection

This Medical Letter on Drugs and Therapeutics article discusses the use of bezlotoxumab in adults with Clostridium difficile infection at high risk for recurrent disease.



JAMA Patient Page 676 Eye Emergencies

#### **NEWS & ANALYSIS**

#### Medical News & Perspectives

598 Half-century After "Summer of Love," Free Clinics Still Play Vital Role

#### The JAMA Forum

601 Reforming Medicaid

#### 603 Global Health

Lethal Heat Waves Expected to Increase Effect of Malaria Initiative

Global Obesity Epidemic Worsening

#### 604 News From the FDA

Faster Orphan Drug Decisions Sickle Cell Therapy Drought Ends New Leukemia, Lymphoma Diagnostic

# Online @ jama.com



# Editor's Audio Summary

Edward H. Livingston, MD, summarizes and comments on this week's issue.

# **Online First Articles**

Visit jamanetwork.com/journals/ jama/newonline for just-published opinion and Medical News articles.

#### **Author Audio Interview**







AUDIO Rita F. Redberg, MD, MSc, Aaron S. Kesselheim, MD, JD, MPH, and Robert M. Califf, MD, discuss their articles characterizing studies used for the approval of high-risk medical devices and accelerated approval of drugs by the FDA.

# Departments

591 Staff Listing

661 CME Questions

673 Classified Advertising

674 Journal Advertiser Index

675 Contact Information

# Instructions for Authors

jama.com/public /Instructionsforauthors.aspx